Your browser doesn't support javascript.
loading
Common severe infections in chronic granulomatous disease.
Marciano, Beatriz E; Spalding, Christine; Fitzgerald, Alan; Mann, Daphne; Brown, Thomas; Osgood, Sharon; Yockey, Lynne; Darnell, Dirk N; Barnhart, Lisa; Daub, Janine; Boris, Lisa; Rump, Amy P; Anderson, Victoria L; Haney, Carissa; Kuhns, Douglas B; Rosenzweig, Sergio D; Kelly, Corin; Zelazny, Adrian; Mason, Tamika; DeRavin, Suk See; Kang, Elizabeth; Gallin, John I; Malech, Harry L; Olivier, Kenneth N; Uzel, Gulbu; Freeman, Alexandra F; Heller, Theo; Zerbe, Christa S; Holland, Steven M.
  • Marciano BE; Laboratory of Clinical Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health (NIH), Bethesda.
  • Spalding C; Laboratory of Clinical Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health (NIH), Bethesda.
  • Fitzgerald A; Laboratory of Clinical Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health (NIH), Bethesda.
  • Mann D; Clinical Research Directorate/Clinical Monitoring Research Program.
  • Brown T; Clinical Research Directorate/Clinical Monitoring Research Program.
  • Osgood S; Laboratory of Clinical Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health (NIH), Bethesda.
  • Yockey L; Laboratory of Clinical Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health (NIH), Bethesda.
  • Darnell DN; Laboratory of Clinical Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health (NIH), Bethesda.
  • Barnhart L; Laboratory of Clinical Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health (NIH), Bethesda.
  • Daub J; Laboratory of Clinical Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health (NIH), Bethesda.
  • Boris L; Clinical Research Directorate/Clinical Monitoring Research Program.
  • Rump AP; Clinical Research Directorate/Clinical Monitoring Research Program.
  • Anderson VL; Laboratory of Clinical Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health (NIH), Bethesda.
  • Haney C; Laboratory of Clinical Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health (NIH), Bethesda.
  • Kuhns DB; Clinical Services Program, Applied Developmental Research Directorate, Leidos Biomedical Research, Inc, Frederick National Laboratory for Cancer Research.
  • Rosenzweig SD; Department of Laboratory Medicine, NIH Clinical Center, Bethesda.
  • Kelly C; Laboratory of Host Defenses, National Institute for Allergy and Infectious Diseases, NIH, Rockville.
  • Zelazny A; Department of Laboratory Medicine, NIH Clinical Center, Bethesda.
  • Mason T; Laboratory of Clinical Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health (NIH), Bethesda.
  • DeRavin SS; Laboratory of Host Defenses, National Institute for Allergy and Infectious Diseases, NIH, Rockville.
  • Kang E; Laboratory of Host Defenses, National Institute for Allergy and Infectious Diseases, NIH, Rockville.
  • Gallin JI; Laboratory of Host Defenses, National Institute for Allergy and Infectious Diseases, NIH, Rockville.
  • Malech HL; Department of Laboratory Medicine, NIH Clinical Center, Bethesda.
  • Olivier KN; Laboratory of Clinical Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health (NIH), Bethesda.
  • Uzel G; Laboratory of Clinical Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health (NIH), Bethesda.
  • Freeman AF; Laboratory of Clinical Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health (NIH), Bethesda.
  • Heller T; Liver Disease Section, National Institute of Diabetes and Digestive and Kidney Diseases, NIH, Bethesda, Maryland.
  • Zerbe CS; Laboratory of Clinical Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health (NIH), Bethesda.
  • Holland SM; Laboratory of Clinical Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health (NIH), Bethesda.
Clin Infect Dis ; 60(8): 1176-83, 2015 Apr 15.
Article en En | MEDLINE | ID: mdl-25537876
ABSTRACT

BACKGROUND:

Chronic granulomatous disease (CGD) is due to defective nicotinamide adenine dinucleotide phosphate oxidase activity and characterized by recurrent infections with a limited spectrum of bacteria and fungi as well as inflammatory complications. To understand the impact of common severe infections in CGD, we examined the records of 268 patients followed at a single center over 4 decades.

METHODS:

All patients had confirmed diagnoses of CGD, and genotype was determined where possible. Medical records were excerpted into a standard format. Microbiologic analyses were restricted to Staphylococcus, Burkholderia, Serratia, Nocardia, and Aspergillus.

RESULTS:

Aspergillus incidence was estimated at 2.6 cases per 100 patient-years; Burkholderia, 1.06 per 100 patient-years; Nocardia, 0.81 per 100 patient-years; Serratia, 0.98 per 100 patient-years, and severe Staphylococcus infection, 1.44 per 100 patient-years. Lung infection occurred in 87% of patients, whereas liver abscess occurred in 32%. Aspergillus incidence was 55% in the lower superoxide-producing quartiles (quartiles 1 and 2) but only 41% in the higher quartiles (rate ratio, <0.0001). Aspergillus and Serratia were somewhat more common in lower superoxide producing gp91phox deficiency. The median age at death has increased from 15.53 years before 1990 to 28.12 years in the last decade. Fungal infection carried a higher risk of mortality than bacterial infection and was the most common cause of death (55%). Gastrointestinal complications were not associated with either infection or mortality.

CONCLUSIONS:

Fungal infections remain a major determinant of survival in CGD. X-linked patients generally had more severe disease, and this was generally in those with lower residual superoxide production. Survival in CGD has increased over the years, but infections are still major causes of morbidity and mortality.
Asunto(s)
Palabras clave

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Aspergilosis / Infecciones Bacterianas / Enfermedad Granulomatosa Crónica Tipo de estudio: Etiology_studies / Incidence_studies / Observational_studies / Risk_factors_studies Límite: Adolescent / Adult / Child / Child, preschool / Female / Humans / Male / Middle aged Idioma: En Año: 2015 Tipo del documento: Article

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Aspergilosis / Infecciones Bacterianas / Enfermedad Granulomatosa Crónica Tipo de estudio: Etiology_studies / Incidence_studies / Observational_studies / Risk_factors_studies Límite: Adolescent / Adult / Child / Child, preschool / Female / Humans / Male / Middle aged Idioma: En Año: 2015 Tipo del documento: Article